Literature DB >> 32496120

Impact of interval timing to surgery on tumor response after neoadjuvant treatment for gastric cancer.

Juan Ocaña Jiménez1, Pablo Priego2, Marta Cuadrado2, Luis Alberto Blázquez2, Silvia Sánchez Picot2, Paula Pastor Peinado3, Federico Longo4, Fernando López5, María Alejandra Caminoa-Lizarralde6, Julio Galindo2.   

Abstract

INTRODUCTION: neoadjuvant chemotherapy (NACT) followed by radical surgery is the optimal approach for locally advanced gastric cancer (GC). Interval timing to surgery after NACT in GC is controversial. The aim of this study was to evaluate the impact of NACT interval time on tumor response and overall survival.
MATERIAL AND METHODS: a retrospective analysis from a prospective database was performed at a single referral tertiary hospital, from January 2010 to October 2018. Patients were assigned to three groups according to the surgical interval time after NACT: < 4 weeks, 4-6 weeks and > 6 weeks. Univariate and multivariable analyses were performed in order to clarify the impact of NACT on post-neoadjuvant pathological complete response rate (ypCR), downstaging (DS) and overall survival (OS).
RESULTS: of the 60 patients analyzed, 18 patients (30 %) had an interval time to surgery < 4 weeks, 26 (43.3 %) between 4-6 weeks and 16 (26.7 %) > 6 weeks. Two patients (3 %) had achieved ypCR and 37 patients (62 %) had achieved DS. There were no differences in DS rates among the interval time groups (p: 0.66). According to the multivariate analysis, only poorly differentiated carcinoma was significantly related to lower DS rates (p: 0.04). Cox regression analysis showed that the NACT interval time had no impact on OS. According to the multivariate analysis, > 25 lymph node harvested (HR: 0.35) and female sex (HR: 5.67) were OS independent predictors.
CONCLUSIONS: the NACT interval time prior gastrectomy for locally advanced GC is not associated with ypCR or DS and has no impact on overall survival.

Entities:  

Mesh:

Year:  2020        PMID: 32496120     DOI: 10.17235/reed.2020.6763/2019

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  2 in total

1.  Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Authors:  Yinkui Wang; Zining Liu; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

2.  Current status and future perspectives on neoadjuvant therapy in gastric cancer.

Authors:  Sheng Ao; Yuchen Wang; Qingzhi Song; Yingjiang Ye; Guoqing Lyu
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.